NanOlogy is in development of investigational drugs enabled by its proprietary particle engineering technology which forms patented large surface area microparticles (LSAMs) of pure drug. Designed for local delivery, NanOlogy LSAMs remain at the disease site releasing molecular drug for weeks with gradual subtoxic clearance.
Clinical results across multiple solid tumors support therapeutic potential in both local and metastatic disease based on sustained tumoricidal response, favorable immunomodulatory effect, and minimal systemic toxicity.
Latest NanOlogy News
-
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic CancerSeptember 12, 2023 -
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational DrugsJune 7, 2023 -
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of CancerMarch 7, 2023 -
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung CancerNovember 11, 2022 -
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTXSeptember 20, 2022 -
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder CancerAugust 1, 2022 -
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast CancerMay 3, 2022 -
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of CareNovember 9, 2021
